can understand that there may be some confusion with the operational support for this study.
The reason why the fully-outsourced model of operations has not been applied in this study is that the planning commenced before the implementation of the new footprint and whilst GSK Clinical operations staff were still in-house. To prevent significant delays to study progression, and downstream rework, it was determined to continue the study with the operations as originally planned (but under GICORS GSK-PPD agreement), whilst seeking the necessary support from PPD. We did however, agree that PPD will execute all agreements for the study so there should be no requirement to complete finance activities for this study within the GSK LOC.
You are correct that any new study placed in Thailand post-transition will be operationalised as a fully-outsourced study.
Darryl has confirmed that the latest version of the SMP provided by Justin Green is correct and the NSC receives the ESR for submission to the regulatory authority. The GSK LOC is the Import License holder for this study but has given POA to the PPD Clinical Study Assistant, Woranoj Kwansirivisal ( who transitioned to PPD from GSK). Woranoj facilitates the Import License but GSK is the license holder (IL). As you know whichever company holds the IL is responsible for submitting safety reports to the Regulatory Authority. At present for this study, the PPD CSA Woranoj has also been given POA for this activity. GSK is therefore still responsible for submitting to the RA. Chalintip Sakolvari, the NSC and compiles the safety reports and Woranoj assists to submit.
The original SMP for the transitional studies will be amended shortly to more accurately show how the process currently works.
Hope this clarifies the situation but please contact the study team, Darryl or myself if you require more information.